News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
273,821 Results
Type
Article (14268)
Company Profile (105)
Press Release (259440)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88269)
Career Advice (465)
Deals (15392)
Drug Delivery (74)
Drug Development (36716)
Employer Resources (50)
FDA (6386)
Job Trends (6232)
News (150704)
Policy (14131)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (15)
Adcomms (8)
Allergies (67)
Alliances (23317)
ALS (56)
Alzheimer's disease (479)
Antibody-drug conjugate (ADC) (99)
Approvals (6577)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1319)
Cardiovascular disease (153)
Career advice (418)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (151)
Cervical cancer (9)
Clinical research (32019)
Collaboration (727)
Compensation (326)
Complete response letters (34)
COVID-19 (779)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1822)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1382)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33460)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (38979)
Executive appointments (528)
FDA (7486)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (429)
Gene editing (70)
Generative AI (18)
Gene therapy (167)
GLP-1 (439)
Government (1404)
Grass and pollen (4)
Guidances (164)
Healthcare (3576)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (69)
Immuno-oncology (14)
Indications (53)
Infectious disease (844)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (60)
IPO (5914)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3448)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (412)
MASH (67)
Medical device (1302)
Medtech (1309)
Mergers & acquisitions (9898)
Metabolic disorders (434)
Multiple sclerosis (47)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (37)
Neuroscience (890)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (600)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (116)
Peanut (12)
People (29742)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8305)
Phase 2 (13518)
Phase 3 (12212)
Pipeline (1910)
Policy (136)
Postmarket research (1401)
Preclinical (3338)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (355)
Real estate (2659)
Recruiting (18)
Regulatory (10961)
Reports (15)
Research institute (574)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (21)
Schizophrenia (69)
Series A (80)
Series B (49)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1644)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (45)
Vaccines (232)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Today (13)
Last 7 days (164)
Last 30 days (669)
Last 365 days (10422)
2026 (965)
2025 (10716)
2024 (12498)
2023 (14246)
2022 (19557)
2021 (20068)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13889)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20890)
Australia (2687)
California (3180)
Canada (1484)
China (551)
Colorado (143)
Connecticut (129)
Delaware (123)
Europe (40871)
Florida (601)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (246)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (421)
Massachusetts (2587)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1397)
New Mexico (7)
New York (906)
North Carolina (619)
North Dakota (2)
Northern California (1449)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (715)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1389)
Tennessee (53)
Texas (455)
United States (12674)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (223)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
273,821 Results for "kalvista pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
January 21, 2026
·
3 min read
·
Dan Samorodnitsky
Press Releases
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2026
February 4, 2026
·
1 min read
Press Releases
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
January 9, 2026
·
6 min read
Press Releases
KalVista Pharmaceuticals to Present at Upcoming November 2025 Investor Conferences
November 5, 2025
·
1 min read
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.
July 9, 2025
·
1 min read
·
Heather McKenzie
Press Releases
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
December 23, 2025
·
5 min read
Press Releases
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
November 10, 2025
·
8 min read
Press Releases
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
October 2, 2025
·
4 min read
Press Releases
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
November 4, 2025
·
1 min read
Approvals
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due to resource constraints and reports surfaced that Commissioner Marty Makary tried to have the application rejected.
July 7, 2025
·
2 min read
·
Tristan Manalac
1 of 27,383
Next
